166 related articles for article (PubMed ID: 23082976)
1. Selective induction of apoptosis: promising therapy in pancreatic cancer.
Liu Z; Li D; Zheng X; Wang E; Wang J
Curr Pharm Des; 2013; 19(12):2259-68. PubMed ID: 23082976
[TBL] [Abstract][Full Text] [Related]
2. Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.
Ferrari S; Severi L; Pozzi C; Quotadamo A; Ponterini G; Losi L; Marverti G; Costi MP
Vitam Horm; 2018; 107():473-513. PubMed ID: 29544641
[TBL] [Abstract][Full Text] [Related]
3. NF-κB in the crosshairs: Rethinking an old riddle.
Bennett J; Capece D; Begalli F; Verzella D; D'Andrea D; Tornatore L; Franzoso G
Int J Biochem Cell Biol; 2018 Feb; 95():108-112. PubMed ID: 29277662
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
5. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer.
Tanaka S
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S197-205. PubMed ID: 25749932
[TBL] [Abstract][Full Text] [Related]
9. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.
Gajate C; Matos-da-Silva M; Dakir el-H; Fonteriz RI; Alvarez J; Mollinedo F
Oncogene; 2012 May; 31(21):2627-39. PubMed ID: 22056873
[TBL] [Abstract][Full Text] [Related]
10. What's new in treatment of pancreatic cancer: a patent review (2010-2017).
Ramos MC; Boulaiz H; Griñan-Lison C; Marchal JA; Vicente F
Expert Opin Ther Pat; 2017 Nov; 27(11):1251-1266. PubMed ID: 28665163
[TBL] [Abstract][Full Text] [Related]
11. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
12. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
13. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.
Cui J; Jiang W; Wang S; Wang L; Xie K
Curr Pharm Des; 2012; 18(17):2464-71. PubMed ID: 22372504
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted cancer drugs highlighted.
Hampton T
JAMA; 2006 Jul; 296(3):270. PubMed ID: 16849654
[No Abstract] [Full Text] [Related]
15. Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system.
Marchesi F; Grizzi F; Laghi L; Mantovani A; Allavena P
Curr Pharm Des; 2012; 18(17):2432-8. PubMed ID: 22372498
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs in the treatment of pancreatic cancer.
Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for the treatment of pancreatic cancer.
Greenhalf W; Thomas A
Anticancer Agents Med Chem; 2011 Jun; 11(5):418-26. PubMed ID: 21521155
[TBL] [Abstract][Full Text] [Related]
18. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
19. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
Bellail AC; Hao C
Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
[No Abstract] [Full Text] [Related]
20. Ultra-violet irradiation induces apoptosis via mitochondrial pathway in pancreatic cancer cells.
Yamauchi T; Adachi S; Yasuda I; Nakashima M; Kawaguchi J; Yoshioka T; Hirose Y; Kozawa O; Moriwaki H
Int J Oncol; 2011 Dec; 39(6):1375-80. PubMed ID: 21894434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
